Traws Pharma (TRAW) Profit After Tax (2012 - 2026)
Traws Pharma (TRAW) posted quarterly Profit After Tax of -$7.1 million for Q1 2026, down 133.11% year-over-year from $21.5 million in Q1 2025, and up 4.41% quarter-over-quarter from -$7.4 million in Q4 2025.
Traws Pharma (TRAW) Profit After Tax (2012 - 2026) Analysis & Trends
Traws Pharma (TRAW) has reported Profit After Tax for 15 consecutive years, with -$7.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Profit After Tax fell 133.11% year-over-year to -$7.1 million; the TTM figure through Mar 2026 stood at -$18.5 million (up 92.4% YoY), while the FY2025 annual figure was $9.2 million, up 105.51% from the prior year.
- Profit After Tax advanced to -$7.1 million in Q1 2026 per TRAW's latest filing, from -$7.4 million in the prior quarter.
- Across five years, Profit After Tax topped out at $21.5 million in Q1 2025 and bottomed at -$133.3 million in Q4 2024.
- Historically, Profit After Tax has averaged -$17.9 million across 5 years, with a median of -$5.0 million in 2024.
- Annual changes were most pronounced in 2024 — Profit After Tax tumbled 3085.18% — and 2025, when it soared 531.27%.
- Traws Pharma's Profit After Tax stood at -$5.4 million in 2022, then gained by 22.8% to -$4.2 million in 2023, then sank by 3085.18% to -$133.3 million in 2024, then jumped by 94.42% to -$7.4 million in 2025, then advanced by 4.41% to -$7.1 million in 2026.
- Business Quant data shows TRAW's Profit After Tax at -$7.1 million in Q1 2026, -$7.4 million in Q4 2025, and -$3.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Traws Pharma | 5.66 Mn | 639,491.99 | - | -3.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.12 Mn |
| Dec 31, 2025 | -7.44 Mn |
| Sep 30, 2025 | -3.04 Mn |
| Jun 30, 2025 | -915,000.00 |
| Mar 31, 2025 | 21.49 Mn |
| Dec 31, 2024 | -133.27 Mn |
| Sep 30, 2024 | -8.48 Mn |
| Jun 30, 2024 | -123.14 Mn |
| Mar 31, 2024 | -4.98 Mn |
| Dec 31, 2023 | -4.18 Mn |
| Sep 30, 2023 | -4.74 Mn |
| Jun 30, 2023 | -4.25 Mn |
| Mar 31, 2023 | -5.78 Mn |
| Dec 31, 2022 | -5.42 Mn |
| Sep 30, 2022 | -5.40 Mn |
| Jun 30, 2022 | -4.02 Mn |
| Mar 31, 2022 | -4.12 Mn |
| Dec 31, 2021 | -3.76 Mn |
| Sep 30, 2021 | -3.45 Mn |
| Jun 30, 2021 | -4.23 Mn |